Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2003
03/20/2003CA2459882A1 Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors
03/20/2003CA2459879A1 3-(4,5,6,7-tetrahydroindol-2-ylmethylidiene)-2-indolinone derivatives as kinase inhibitors
03/20/2003CA2459766A1 Oxazolidinone and/or isoxazoline as antibacterial agents
03/20/2003CA2459760A1 Method for preparing unsaturated fatty hydroxy-acids and esters thereof, their use in pharmaceutical and/or cosmetic compositions
03/20/2003CA2459533A1 Methods of treating pulmonary disease
03/20/2003CA2459531A1 Heterocyclic substituted 2- (4-phenoxy) pyridine derivatives and related compounds as sodium channel blockers for the treatment of neuronal damage and neurodegenerative conditions
03/20/2003CA2459527A1 Aryl substituted pyridinecarboxamides and their use as sodium channel blockers
03/20/2003CA2459515A1 Indole derivatives
03/20/2003CA2459469A1 Pharmaceutical composition for diabetic neuropathy
03/20/2003CA2459464A1 Tetrahydropyran derivatives and their use as therapeutic agents
03/20/2003CA2459457A1 Benzothiazepine derivatives for the treatment of hyperlipidemia
03/20/2003CA2459445A1 Benzothiepine ileal bile acid transport inhibitors
03/20/2003CA2459364A1 Ccr-3 receptor antagonists v
03/20/2003CA2459318A1 Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer
03/20/2003CA2459310A1 Method and composition for treating immune complex associated disorders
03/20/2003CA2459308A1 Cbi analogues of cc-1065 and the duocarmycins
03/20/2003CA2459304A1 Combination of an adenosine a2a receptor antagonist and an antidepressant or anxiolytic
03/20/2003CA2459168A1 Method for the preparation of hexahydro-furo[2,3-b]furan-3-ol
03/20/2003CA2458628A1 Use of substituted aminomethyl chromans in the treatment of movement disorders
03/20/2003CA2458029A1 Methods of treating cytokine mediated diseases
03/20/2003CA2457895A1 Prostaglandin compositions and methods of treatment for male erectile dysfunction
03/20/2003CA2457848A1 Use of 4-pyridylmethylphthalazines for cancer treatment
03/20/2003CA2457835A1 Crystalline forms of valacyclovir hydrochloride
03/20/2003CA2457717A1 Use of compounds in a dry powder inhaler
03/20/2003CA2457282A1 Method for expression of small antiviral rna molecules within a cell
03/20/2003CA2455990A1 Methods for diagnosing and treating diseases and conditions associated with protein kinase c.lambda.
03/20/2003CA2452194A1 Sustained release pharmaceutical compositions comprising a silicone support material
03/20/2003CA2357511A1 Genital lubricating compositions and uses thereof
03/19/2003WO2002024001A2 Animal feed supplement containing d-pantothenic acid and/or its salts, improved method for the production thereof, and its use
03/19/2003WO2002023992A1 Disinfectant agent
03/19/2003EP1293565A2 Mammalian telomerase RNA component
03/19/2003EP1293507A1 Process for producing crystal
03/19/2003EP1293506A1 New 1-(1-(Hetero)aryl-1-perhydroxyalkylmethyl)-Piperazine derivatives, process for their preparation and pharmaceutical compositions containing the same
03/19/2003EP1293503A1 Triazole derivatives
03/19/2003EP1293493A2 Process for the preparation of meso-zeaxanthine
03/19/2003EP1293214A2 LTB4 antagonists and radiopharmaceuticals for imaging infection and inflammation
03/19/2003EP1293213A1 Preventives/remedies for postoperative stress
03/19/2003EP1293211A1 Combinations of ileal bile acid transport inhibitors and bile acid sequestering agents for cardiovascular indications
03/19/2003EP1293210A1 Means and method for hormonal contraception
03/19/2003EP1293209A1 Oral pharmaceutical dosage forms with reduced potential for drug abuse
03/19/2003EP1293208A1 Pharmaceutical formulation
03/19/2003EP1293207A1 Use of ritonavir (ABT-538) for improving the pharmacokinetics of drugs metabolized by cytochrome P450 in a method of treating aids
03/19/2003EP1293206A1 Water-based liquid preparation
03/19/2003EP1293205A1 Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease
03/19/2003EP1293204A1 Urea-containing gel preparation
03/19/2003EP1293203A1 Alcohol based local anaesthetic formulation
03/19/2003EP1293202A1 Remedies for degenerative arthritis
03/19/2003EP1293201A2 Use of aminoadamantane compounds as immunoregulators
03/19/2003EP1293200A1 Nerve growth factor activity potentiating agents
03/19/2003EP1293198A1 Device for transdermal administration for the treatment of urinary tract disorders
03/19/2003EP1293197A1 Process for producing phospholipid-containing drugs
03/19/2003EP1293195A1 Oral pharmaceutical dosage forms with reduced potential for drug abuse, comprising respiratory irritants or bitter substances
03/19/2003EP1293194A1 Physically stable sprayable gel composition
03/19/2003EP1293193A1 Use of pantetheine sulfonic acid and/or salts thereof as anti-radical agent
03/19/2003EP1293131A1 Throat care agents
03/19/2003EP1293126A1 Ophthalmic solution and contact lens solution
03/19/2003EP1292709A1 Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
03/19/2003EP1292676A1 Mutation associated with epilepsy
03/19/2003EP1292674A2 Nucleotide sequences involved in increasing or decreasing mammalian ovulation rate
03/19/2003EP1292668A2 Gene disruption methodologies in fungi for drug target discovery
03/19/2003EP1292667A2 Identification and use of molecular markers indicating cellular reprogramming
03/19/2003EP1292616A2 Nucleic acids encoding a regulator of g protein signaling, rgs18, and uses thereof
03/19/2003EP1292607A2 Novel solid body forms of mesoprogestin 11beta- 4e-(hydroxyiminomethyl)-phenyl]-17alpha-methoxymethyl-17beta-methoxy-estra-4,9-dien-3-one
03/19/2003EP1292605A2 Antisense modulation of inhibitor of dna binding-1 expression
03/19/2003EP1292604A1 2-aminocarbonyl-9h-purine derivatives
03/19/2003EP1292603A2 Methods and compositions for treating hepatitis c virus
03/19/2003EP1292601A2 Naaladase inhibitors for treating retinal disorders and glaucoma
03/19/2003EP1292598A1 Process for drying amoxicillin
03/19/2003EP1292597A1 Carbamate and thiocarbamate podophyllotoxin derivatives, preparation method and pharmaceutical compositions containing them
03/19/2003EP1292596A1 1,3,8-triaza-spiro[4,5]decan-4-one derivatives as neurokinin receptor antagonists
03/19/2003EP1292595A1 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione hydriodide as pharmaceutical
03/19/2003EP1292594A1 Quinazoline derivatives for the treatment of tumours
03/19/2003EP1292592A1 Heterocyclic aminoalkyl pyridine derivatives as psychopharmaceuticals
03/19/2003EP1292591A2 Substituted bicyclic derivatives for the treatment of abnormal cell growth
03/19/2003EP1292590A1 Admantane derivatives
03/19/2003EP1292589A2 Methods for producing chiral chromones, chromanes, amino substituted chromanes and intermediates therefor
03/19/2003EP1292586A1 Process for the preparation of pyrazolopyrimidinones
03/19/2003EP1292581A1 Bicyclic cyclohexylamines and their use as nmda receptor antagonists
03/19/2003EP1292580A1 Pyrazine and imidazopyrazine derivatives as antioxidants
03/19/2003EP1292579A1 Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
03/19/2003EP1292577A2 Aryl substituted pyrazoles, triazoles and tetrazoles as sodium channel blocker
03/19/2003EP1292576A1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
03/19/2003EP1292575A2 1-aryl-4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents
03/19/2003EP1292574A1 3-azabicyclo[3.1.0]hexane derivatives having opioid receptor affinity
03/19/2003EP1292573A2 Substituted thioacetamides
03/19/2003EP1292572A1 Propanolaminotetralines, preparation thereof and compositions containing same
03/19/2003EP1292568A2 Benzamide ligands for the thyroid receptor
03/19/2003EP1292564A2 Aminoalcohol derivatives
03/19/2003EP1292563A2 Compounds useful for the preparation of medicaments with phosphodiesterase iv inhibitory activity
03/19/2003EP1292562A1 Triterpenoid derivatives
03/19/2003EP1292381A1 Process and device for producing liquid dosage formulations
03/19/2003EP1292363A2 Carboxyalkylether-acat inhibitor combinations
03/19/2003EP1292347A1 Drug delivery apparatus
03/19/2003EP1292337A2 Multivalent platform molecules comprising high molecular weight polyethylene oxide
03/19/2003EP1292336A2 Conjugates of aminodrugs comprising an oxime bond
03/19/2003EP1292332A2 Adjuvants and processes to induce a specific type of immune response
03/19/2003EP1292331A2 Immunostimulatory rna/dna hybrid molecules
03/19/2003EP1292320A2 Extracts from spermatophyte plants with immunomodulating activity
03/19/2003EP1292319A2 Extracts from spermatophyte plants with antitumor activity
03/19/2003EP1292316A1 Hemostatic compositions of polyacids and polyalkylene oxides and methods for their use
1 ... 5530 5531 5532 5533 5534 5535 5536 5537 5538 5539 5540 5541 5542 5543 5544 5545 5546 5547 5548 5549 5550 ... 7860